What are the side effects of Tisotumab Vedotin-tftv?

Tisotumab Vedotin-tftv, sold under the brand name Tivdak, is a medication used for the treatment of certain types of cancer. Like all medications, Tisotumab Vedotin-tftv can cause side effects. It's important for patients and healthcare providers to be aware of these potential side effects to manage them effectively.

**Common Side Effects:**
The most frequently reported side effects of Tisotumab Vedotin-tftv include fatigue, nausea, hair loss, and dry eyes. Many patients also experience peripheral neuropathy, which is characterized by numbness, tingling, or pain in the hands and feet. Additionally, infusion-related reactions such as fever, chills, and shortness of breath may occur during or shortly after administration of the drug.

**Serious Side Effects:**
While many of the common side effects can be managed with supportive care and symptomatic treatment, there are also more serious side effects that require immediate medical attention. These include severe infections, bleeding, and vision problems. Patients may experience severe abdominal pain, which can be a sign of gastrointestinal perforation. Another serious side effect is keratitis, an inflammation of the cornea that can lead to vision changes or loss if not treated promptly.

**Long-term Side Effects:**
Long-term use of Tisotumab Vedotin-tftv can lead to chronic conditions such as persistent peripheral neuropathy. This can significantly impact a patient's quality of life, as the numbness or pain can become debilitating. Additionally, long-term effects on the liver and kidneys may occur, necessitating regular monitoring of liver and kidney function during treatment.

**Managing Side Effects:**
Management of side effects is a crucial aspect of treatment with Tisotumab Vedotin-tftv. Patients should report any new or worsening symptoms to their healthcare provider immediately. Supportive treatments, such as anti-nausea medications and pain relievers, can alleviate some of the discomfort. Regular eye examinations are recommended to detect and treat ocular side effects early. In some cases, dose adjustments or temporary discontinuation of the drug may be necessary.

**Precautions and Monitoring:**
Before starting treatment with Tisotumab Vedotin-tftv, patients should be thoroughly evaluated to ensure they are suitable candidates for this medication. Blood tests are usually performed to assess liver and kidney function, and baseline neurological assessments are recommended to monitor for peripheral neuropathy. During treatment, regular follow-up appointments are essential to monitor for side effects and adjust the treatment plan as needed.

In conclusion, while Tisotumab Vedotin-tftv offers a valuable treatment option for certain cancer patients, it is not without its risks. Awareness and proactive management of side effects can help mitigate some of the risks associated with this medication. Patients and healthcare providers must work closely together to ensure that the benefits of treatment outweigh the potential side effects.